• Oncolytics Biotech disclosed new durability results from REO 022 in second-line RAS-mutant, microsatellite-stable metastatic colorectal cancer, with results already presented as new data in its update.
• Pelareorep-based combination therapy showed sustained tumor response versus typical outcomes in this treatment setting.
• Response activity also compared favorably with standard care benchmarks, supporting a stronger clinical benefit profile.
• Company is enrolling a randomized Phase 2 study of pelareorep with FOLFIRI and bevacizumab in the same population.
• FDA discussions are underway on a potential accelerated approval path, centered on response durability and time-to-event measures from the ongoing trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oncolytics Biotech Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605040900PRIMZONEFULLFEED9711743) on May 04, 2026, and is solely responsible for the information contained therein.